Acute Myeloid Leukemia

Potential new treatments for acute myeloid leukemia

Two separate studies yield key findings for the prevention, diagnosis, treatment and cure for acute myeloid leukemia (AML). AML is a group of heterogeneous diseases with considerable diversity in terms of genetic abnormalities. ...

Nov 25, 2013
popularity1 comments 0

Two-faced leukemia?

One kind of leukemia sometimes masquerades as another, according to a study published online this week in the Journal of Experimental Medicine.

Dec 12, 2011
popularity0 comments 0

Promising drug a 'new paradigm' for treating leukemia

Researchers at the University of Virginia School of Medicine have developed a compound that delays leukemia in mice and effectively kills leukemia cells in human tissue samples, raising hopes that the drug could lead to improved ...

Mar 25, 2015
popularity19 comments 0

Acute myeloid leukemia (AML), also known as acute myelogenous leukemia, is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting for approximately 1.2% of cancer deaths in the United States, its incidence is expected to increase as the population ages.

The symptoms of AML are caused by replacement of normal bone marrow with leukemic cells, which causes a drop in red blood cells, platelets, and normal white blood cells. These symptoms include fatigue, shortness of breath, easy bruising and bleeding, and increased risk of infection. Several risk factors and chromosomal abnormalities have been identified, but the specific cause is not clear. As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.

AML has several subtypes; treatment and prognosis varies among subtypes. Five-year survival varies from 15–70%, and relapse rate varies from 33-78%, depending on subtype. AML is treated initially with chemotherapy aimed at inducing a remission; patients may go on to receive additional chemotherapy or a hematopoietic stem cell transplant. Recent research into the genetics of AML has resulted in the availability of tests that can predict which drug or drugs may work best for a particular patient, as well as how long that patient is likely to survive.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

Closer view of the brain

For Harvard neurobiologist Jeff Lichtman, the question hasn't been whether scientists will ever understand the brain, but how closely they'll have to look before they do.

Breast cancer drug beats superbug

Researchers at University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences have found that the breast cancer drug tamoxifen gives white blood cells a boost, better enabling ...